Palatin Q3 net loss $8.4M; Phase 3 DED study meets pain endpoint, 7 of 11 secondary endpoints

PALATIN TECHNOLOGIES INC

2025-Q3 EPS reported -$1.53 revenue$4,140,090

Phase 3 MELODY-1 for PL9643 in dry eye disease met co-primary pain endpoint (P<0.025) and 7 of 11 secondary endpoints at 12 weeks; rapid onset at 2 weeks.
No revenue in Q3 (Vyleesi rights sold Dec 2023); net loss $8.4M ($0.53 loss per share) vs $8.7M ($0.76) a year ago.
Cash and equivalents $10.0M as of March 31, 2024; expects to fund operations into 2H calendar 2024; raised $10M in registered direct offering in Jan 2024.
Obesity: Phase 2 trial of MCR4 agonist + GLP-1 targeted to start Q2 2024 with topline data in 2H 2024.
Male ED: Phase 2 trial of bremelanotide + PDE5i in non-responders targeted to start Q2 2024, topline expected 2H 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PALATIN TECHNOLOGIES INC reported financial results for fiscal third quarter ended March 31, 2024.

Period: fiscal third quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 15, 2024, we issued a press release including results for our quarter ended March 31, 2024

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

PALATIN TECHNOLOGIES INC filing history →

Source: SEC EDGAR

accession 0001654954-24-006304

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.